Evidence map›Paper›PMID 41596495›Full record

ArticleInternational journal of molecular sciences2026

Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer's Disease: A Pilot Study.

Pin-Chieh Hsu, Jia-Ying Yang, Ling-Chun Huang, Yuan-Han Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pin-Chieh HsuSchool of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
Jia-Ying YangSchool of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
Ling-Chun HuangSchool of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.ORCID 0000-0001-9304-0359
Yuan-Han YangSchool of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.ORCID 0000-0002-1918-9021

Funding

Department of Neurology, Kaohsiung Medical University Gangshan Hospital KMGH-113G015Kaohsiung Medical University Research Center KMU-TC113B02National Health Research Institutes Grant NHRI-11A1-CG-CO-06-2225-1National Health Research Institutes Grant NHRI-12A1-CG-CO-06-2225-1National Health Research Institutes Grant NHRI-13A1-CG-CO-06-2225-1National Health Research Institutes Grant NHRI-14A1-CG-CO-06-2225-1
6 · The paper itself

Abstract

Previous studies have shown that plasma amyloid-beta oligomers (AβOs), the toxic form of amyloid-beta (Aβ), are a critical issue in the development or worsening of Alzheimer's disease (AD) and can be regarded as a blood marker for screening in dementia. We examined plasma AβOs with their related biomarkers in a case-control study to clarify these issues. A total of 16 patients diagnosed with Alzheimer's dementia (AD) and 16 cognitively normal controls (NCs) were recruited to compare their plasma biomarkers, AβO, Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide FragmentsAgedAged, 80 and overBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedPilot ProjectsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide FragmentsAlzheimer’s diseaseamyloid-beta oligomerblood-based diagnosisearly detectionplasma biomarkers

Identifiers

PMID41596495
PMCPMC12841111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.